Building a System to Prevent, Recognize, and Treat Substance Exposure Infants
Jennifer Donahue1,3 and Emily Knearl2,3
1. Child Protection Accountability Commission
2. Division of Public Health
3. Substance Exposed Infants In-Depth Technical Assistance (SEI IDTA)

Delaware and the nation are struggling with an addiction epidemic, a fact that is well known. Less well known is that the addiction epidemic is impacting pregnant women and their infants in increasing numbers. In 2016, there were 431 reports of substance exposed infants to the Department of Services for Children, Youth and Their Families, a sharp increase from the previous year.

The two most common substances found at birth in Delaware are marijuana and opioids; both of which are tied to either short and/or long term negative consequences for the infant. Alcohol exposure, which has the most well-documented long term negative impacts on an infant, is virtually impossible to detect immediately following birth.

In 2016, Delaware was one of the states selected for Substance Exposed Infants In-Depth Technical Assistance (SEI IDTA) funded by the U.S. Department of Substance Abuse and Mental Health Services Administration, and offered by the National Center on Substance Abuse and Child Welfare. The Delaware Child Health Protection Accountability Commission, Department of Health and Social Services, Department of Services for Children, Youth and their Families, March of Dimes, Delaware Healthy Mothers and Infant Consortium, Fetal Alcohol Task Force, Connections, medical providers, and many others have begun work to:

- Increase screening of reproductive age women who may be at risk for substance abuse addiction, and increase links to treatment and home visiting services;
- Educate physicians on the signs and symptoms of addiction in pregnant patients, and how to refer patients to treatment (See Figures 1 and 2);
- Reduce stigma around maternal substance use, and highlight the role of addiction as a chronic disease and the importance of connecting families to support, not punitive measures;
- Develop a system where infants born substance exposed and their families receive the medical treatments and supports they need as part of the federally-required “Plan of Safe Care” process. The revised federal rule requires states to address the health and substance use disorder treatment needs of the infant and family.
- Link to the Delaware Contraception Access Now (DE CAN) program to help women get access to effective contraception immediately post-partum.

Pregnant women often do not realize the extent to which alcohol and drug use can harm their baby, and we know that women struggling with addiction are less likely to access prenatal care and significantly more likely to have an unplanned pregnancy.
Under Delaware Code, Title 24, Chapter 17 (Medical Practice Act), Subchapter V, § 1769A, http://delcode.delaware.gov/title24/c017/sc05/index.shtml, medical providers are required to educate their pregnant patients on the dangers of using alcohol and drugs during pregnancy. The Division of Public Health is charged with developing those messages. Working closely with the SEI IDTA partners, DPH created information to meet the requirements of the law, and provide medical providers the tools they need to screen their patients, educate them on the dangers of substance use, and provide links to treatment. This fall the materials will distributed to medical providers serving reproductive age women and placed on the Help is Here website. (See Figures 3, 4, 5, and 6)

For further information, call the Division of Public Health at 302-744-4704. For further information on preventing, recognizing, and treating addiction, visit www.helpisherede.com.

Figures 1 and 2. Fact Sheet: Substance Abuse During Pregnancy

**Fact Sheet for Medical Providers: SUBSTANCE USE DURING PREGNANCY**

Delaware law requires that medical providers educate pregnant patients about the dangers of substance use:

DE Code, Title 24, Chapter 17, § 1769A. Required warning to pregnant women of possible effects of using alcohol, cocaine, or other narcotics.

1. A person convicted to practice medicine who treats, advises, or consults with pregnant women on matters relating to the pregnancy shall post written, concise, and specific warnings to pregnant women of the dangers of using alcohol, tobacco, marijuana, and other substances, including the potential for harm to their fetuses and the newborn, and the likelihood of birth defects and other adverse outcomes related to the use of alcohol, tobacco, marijuana, and other substances during pregnancy.

2. A person who treats, advises, or consults with pregnant women pursuant to subsection (a) of this section and who is convicted of a gross misdemeanor may be sentenced to a term of imprisonment not to exceed one year as provided by this section.

3. The Director of the Division of Public Health shall prescribe the form and content of the warnings required pursuant to this section.

### Quick Summary of Substance Effects

<table>
<thead>
<tr>
<th>Short-term Effects/Birth Outcome</th>
<th>Nicotine</th>
<th>Alcohol</th>
<th>Marijuana</th>
<th>Opioids</th>
<th>Cocaine</th>
<th>Methadone/Phenylethylamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal Growth</td>
<td>Effect</td>
<td>Strong Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td></td>
</tr>
<tr>
<td>Anomalies</td>
<td>No Effect</td>
<td>Strong Effect</td>
<td>No Effect</td>
<td>No Effect</td>
<td>No Effect</td>
<td></td>
</tr>
<tr>
<td>Withdrawal</td>
<td>No Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Strong Effect</td>
<td>No Effect</td>
<td>Effect</td>
</tr>
<tr>
<td>SUBSTANCE ABUSE</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td></td>
</tr>
</tbody>
</table>

### Long-term Effects/Birth Outcome

<table>
<thead>
<tr>
<th>Growth</th>
<th>No Effect</th>
<th>Strong Effect</th>
<th>No Effect</th>
<th>No Effect</th>
<th>No Effect</th>
<th>No Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behavior</td>
<td>Effect</td>
<td>Strong Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
</tr>
<tr>
<td>Cognition</td>
<td>Effect</td>
<td>Strong Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
</tr>
<tr>
<td>Language</td>
<td>Effect</td>
<td>No Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
</tr>
<tr>
<td>Achievement</td>
<td>Effect</td>
<td>Strong Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
<td>Effect</td>
</tr>
</tbody>
</table>

What to tell your patients

No amount of alcohol, marijuana, or other illegal drugs is safe for you or your baby. Prescription opioids should be taken exactly as prescribed and babies may experience neonatal abstinence syndrome (NAS) after birth, which will likely need medical intervention.

From the American College of Obstetricians and Gynecologists:

“Cocaine’s effects on the developing brain are just one reason why smoking, drinking, or taking drugs during pregnancy is not recommended. Women who smoke, drink, or use drugs during pregnancy put their baby at risk for birth defects and problems. Drugs can interfere with the growth of the fetus and can cause problems at birth and after birth.”

Figures 3, 4, 5, and 6. Guidance for Screening Pregnant Patients for Substance Abuse
GUIDANCE FOR MEDICAL PROVIDERS:
How to Screen Pregnant Patients for Substance Use Disorder and Alcohol Use

RECOMMENDATION

All pregnant women should be educated on the dangers of substance use during pregnancy and screened for substance use disorder and alcohol use, particularly during the first and third trimesters.

The American College of Obstetricians and Gynecologists (ACOG) recommends universal screening with brief intervention and treatment referrals for cannabis, alcohol, club drugs, dissociative drugs, hallucinogens, opioids, stimulants, tobacco, and other compounds such as anabolic steroids and inhalants.

BACKGROUND

No amount of alcohol, marijuana, illegal drugs, or tobacco is safe for the mother or baby. Alcohol is still the number one cause of preventable birth defects, and even minimal alcohol exposure can harm a fetus. Data shows there are short- and long-term negative impacts of alcohol, tobacco, opioids, and other drugs use on the mother and baby.

For further information on the dangers of substance use during pregnancy, see Fact Sheet for Medical Providers: Substance Use During Pregnancy in your packet.

Legal prescription drugs, including opioids, should be closely monitored and used exactly as prescribed. For mothers who consumed opioids legally as part of a treatment plan, their infants will still likely need treatment for neonatal abstinence syndrome (NAS) following birth.

Any pregnant woman who is on legal or illegal opioids should not cease her use immediately or there may be significant risks to the fetus. Conversion to Medication Assisted Treatment (MAT) is preferred for women seeking to discontinue use of illegal or legal opioids during pregnancy (see page 4).

To learn more about MAT treatment locations for pregnant women, visit the Substance Abuse and Mental Health Services Administration (SAMHSA) website at www.samhsa.gov or call 800-653-8253 in New Castle County and 800-345-6785 in Kent and Sussex counties.

OPPIODS AND PAIN MANAGEMENT

Legally prescribed opioids are a proven pipeline to opioid dependence. Nearly 80 percent of heroin users report they started with prescription opioids. And, the benefits of long-term opioid therapy for chronic pain is not well supported by the evidence.

Prescribers of opioids for pain management should consider recommending alternatives to opioid medications, including non-opioid medications, exercise and physical therapy, behavioral therapy, and relaxation techniques. For patient and physician opioid fact sheets and links to regulation, visit Help is Here: www.helpishere.de.com/Health-Care-Providers.
CONSIDERATIONS

Substance use disorder is a chronic disease. Similar to diabetes and other illnesses that can harm a mother or her baby during pregnancy, a potential substance use problem should be identified and addressed early through screening using a validated screening tool. ACOG recommends that routine screening for substance use disorder be applied equally to all people, regardless of age, sex, race, ethnicity, or socioeconomic status.

You have an important role in educating women on the dangers of substance abuse during pregnancy, screening women for substance use disorder, and referring those with a potential substance use disorder. The goal is to help the mother and her baby. Education, screening, and referrals should be integrated seamlessly into regular prenatal visits.

Be nonjudgmental and reassuring. You are more likely to get honest responses if the patient feels comfortable and safe. When asking about substances, pregnant patients may naturally be concerned about admitting drug or alcohol use. They may fear stigma or that they will be reported to child protective services.

Pregnant women cannot be penalized for substance use during pregnancy under the law. Medical providers do not have a legal requirement or obligation to report substance use in pregnant women or to perform testing to confirm suspected use. In fact, child protective services will not take a report for behavior while pregnant as that is outside their legal authority.

Under federal law, pregnant women must receive priority substance abuse treatment. To learn more about what treatment services are available, visit www.HelpHerNoDF.com.

GENERAL SCREENING RECOMMENDATIONS

STEP ONE: START THE CONVERSATION

Following the SBI model (Screening, Brief Intervention and Referral to Treatment), start the conversation in a reassuring and compassionate matter. “Can I ask you about drug or alcohol use? This information is important to working with you to have a healthy pregnancy.”

Be reassuring. Be clear the information will not be used against the patient or impact her ability to keep custody of the child. Emphasize the importance of your commitment to help her have a healthy pregnancy.

STEP TWO: DO THE SCREENING

Use the screening tool that works best for your practice and your population. The next page includes three validated screening tools that can be used easily in a health care setting. All seek to identify potential issues that would require further dialogue with the patient and referrals to treatment providers for further assessment. These screening tools are in the public domain and recognized by the Substance Abuse and Mental Health Services Administration (SAMHSA).
GENERAL SCREENING TOOLS

"Screening" means using a validated screening tool to ask questions aimed at understanding the patient's potential substance use. There are several validated screening tools for pregnant women, including 4Ps, T-ACE, and CRAFFT for adolescents and young adults.

THE 4 PS

4 Ps for Substance Abuse:
1. Have you ever used drugs or alcohol during Pregnancy?
2. Have you had a problem with drugs or alcohol in the Past?
3. Does your Partner have a problem with drugs or alcohol?
4. Do you consider one of your Parents to be an addict or alcoholic?

Scoring: A patient with 2 or 3 yes answers should be referred for further assessment.

Source: Adapted from Being A Medical Greater, Erin Berne, Project, Carol Caesar, Canary, 1111, Aliso Street, Santa Ana, CA.

T-ACE

ACOG recommends the T-ACE screening tool for alcohol, specifically developed for use with pregnant women. Ask patients four questions:

T: Tolerance: How many drinks does it take to make you high?
A: Have you felt need to cut down on your drinking?
C: Have you ever had a drink the first thing in the morning to steady your nerves or get rid of a hangover?
E: Eye opener: Have you ever been annoyed by criticism of your drinking?

Scoring: Any woman who answers "yes" to more than two questions is scored two points. A score of two or more is considered a positive screen, and the woman should be referred for further assessment.


CRAFFT – SUBSTANCE ABUSE SCREEN FOR ADOLESCENTS AND YOUNG ADULTS

C: Have you ever ridden in a car driven by someone (including yourself) who was high on drugs or alcohol?
R: Do you ever use alcohol or drugs to RELAX, feel better about yourself, or fit in?
A: Do you ever use alcohol or drugs while you are by yourself, ALONE?
F: Do you ever FORGET things you did while using drugs or alcohol?
F: Do friends or FAMILY ever tell you that you should cut down on your drinking or drug use?
T: Have you ever gotten in TROUBLE while you were using alcohol or drugs?

Scoring: Two or more positive items indicate the need for further assessment.


TOBACCO

While this guidance focuses on alcohol, illegal substances, and prescription drug abuse, screening for tobacco is still recommended. The negative impact of tobacco use on birth outcomes is well documented. If a patient indicates they smoke, consider referrals to the Delaware Quits program for free cessation resources and tools at www.quitdels.com or by calling 1-866-405-1858.
STEP THREE: EDUCATE THE PATIENT AND PROVIDE REFERRALS

If the screening tool does not identify a potential problem:

- State law requires that all medical providers serving pregnant women counsel them on the dangers of any alcohol, marijuana, or other drug use during pregnancy. Recommend they cease use with the exception of opioids, which require special considerations and may need to involve Medication Assisted Treatment. For further information on the dangers of substance use during pregnancy, see the fact sheet provided in your packet.

If the screening tool does identify a risk for substance use disorder:

- Be clear that you know the mother wants to be as healthy as possible for her baby and herself, and that she can reduce the health risk to them both by stopping using alcohol and drugs.

- Discuss possible strategies for her to stop — individual or group counseling, 12-step program, or substance use disorder treatment. If she is struggling with opioid addiction, Medication Assisted Treatment should be discussed.

- Recommend woman visit www.Health4HerDE.com or call 800-852-2919 in New Castle County and 800-898-6785 in Kent or Sussex counties to learn more about services for pregnant women.

MEDICATION ASSISTED TREATMENT

Medication Assisted Treatment (MAT) is an important part of the treatment regime for pregnant women and is proven to improve outcomes. According to ACOG, “the rationale for medication assisted treatment during pregnancy is to prevent complications from illicit opioid use and narcotic withdrawal, encourage prenatal care and drug treatment, reduce criminal activity, and avoid risks to the patient associated with a drug culture.” (ACOG Committee Opinion, Opioid Abuse, Dependence and Addiction in Pregnancy, Number 526, May 2012, page 2).

The two main medications involved in MAT for pregnant women are methadone and buprenorphine (without Naloxone). The decision regarding which appropriate medication should be made jointly with the MAT provider, the obstetrician, and the woman.

<table>
<thead>
<tr>
<th>METHADONE</th>
<th>BUPRENORPHINE (WITHOUT NALOXONE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>* May have better treatment retention</td>
<td></td>
</tr>
<tr>
<td>* No risk precipitating withdrawal</td>
<td></td>
</tr>
<tr>
<td>* Patients with more severe opioid use disorder</td>
<td></td>
</tr>
<tr>
<td>* Probably less severe NAS; works best in patients needing less monitoring</td>
<td></td>
</tr>
<tr>
<td>* Reduced risk of overdose during induction</td>
<td></td>
</tr>
<tr>
<td>* Reduced risk of overdose if children are exposed to medication</td>
<td></td>
</tr>
</tbody>
</table>

Sources: Substance Abuse and Mental Health Services Administration, https://www.samhsa.gov/.

SOURCES

For a full list of sources, call the Division of Public Health at 302-744-4704.

Update 04/16/17

Page 4 of 4

Copyright (c) 2017 Delaware Academy of Medicine / Delaware Public Health Association.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.